China has recently completed its 2009–11 healthcare reform. The reform has come at a high cost: although the Ministry of Health intended to invest CNY850bn ($135bn) in the plan, total investment has now exceeded CNY1,100bn ($175bn).
Author: Ling Sun
Publisher: Datamonitor Healthcare
Number of pages:14
Report code:DMKC 0085013
China has recently completed its 2009–11 healthcare reform. The reform has come at a high cost: although the Ministry of Health intended to invest CNY850bn ($135bn) in the plan, total investment has now exceeded CNY1,100bn ($175bn). While it is unclear why the total investment exceeded the budget, it is evident that the Chinese healthcare system in general is largely underfunded.
Features and benefits
Review the principle aims of the 2009-11 round of regulatory reform in China.
Analyze key aspects of the new Five-Year Plan.
2012 marks the beginning of China’s 12th Five-Year Plan, which encompasses changes from several ministries. The Ministry of Health also issued the Work Paper on the Deepening of Healthcare Reform (2011–15).
Different goals established by these plans outline the future of the entire industry and provide both opportunities and challenges to drugmakers and other stakeholders.
Table of Contents
4 REGULATORY UPDATE
4 China underwent significant healthcare reform over 2009–11
5 “Zero markup” piloted to separate prescribing and dispensing
6 Reforms look to curb antibiotic over-prescribing
7 Routine price cuts to drive down prices
11 Anhui model questioned; new model tested in Sangzhi
12 EDL expansion expected by the end of 2012
13 Physician-patient relationship is deteriorating 14 BIBLIOGRAPHY
LIST OF FIGURES
4 Figure 1: Principal aims of the 2009–11 Chinese healthcare reform
7 Figure 2: Details of the last four rounds of price cuts in China, 2010–12
8 Figure 3: Pariet (rabeprazole) and generic rabeprazole: an example of the latest round of price
10 Figure 4: Impacts of the price cuts on multinational companies, 2012
11 Figure 5: Problems with the Anhui model
12 Figure 6: Expansion of the Chinese Essential Drug List, 2012
LIST OF TABLES
5 Table 1: 2009–11 healthcare reform and in the 12th Five-Year Plan: main objectives
Figure 1: Principal aims of the 2009-11 Chinese healthcare reform
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.